The clinical study for the leuprolide implant to treat Alzheimer's disease has now completed enrolment and the trial programme will begin in the second half of 2005 in the USA and Europe.
US company Voyager Pharmaceutical Corp is going ahead with the trials, following acceptance by the US Food and Drug Administration of its Investigational New Drug Application and clinical protocol in late December, 2004.
The leuprolide acetate product is delivered through US company Durect Corp's trademarked Durin biodegradable implant technology. This is a platform for short- and long-term parenteral drug delivery, based on the use of biodegradable polymer excipients with a …
Комментариев нет:
Отправить комментарий